Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines

被引：9
作者：
Shoor, Stanford [1 ]
机构：
[1] Stanford Univ, 1000 Welch Rd Suite 203, Palo Alto, CA 94304 USA
来源：
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2020年 / 34卷 / 02期
关键词：
Serious infection; Co-stimulatory molecule inhibitors; IL-17 and IL-23 inhibitors; MODIFYING ANTIRHEUMATIC DRUGS; NECROSIS-FACTOR INHIBITORS; SEVERE PLAQUE PSORIASIS; LONG-TERM EFFICACY; RHEUMATOID-ARTHRITIS; PHASE-III; FUSION PROTEIN; MODERATE; SAFETY; BELATACEPT;
D O I：
10.1016/j.idc.2020.02.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Co-stimulatory T-cell inhibitors are used in the treatment of rheumatoid arthritis and to prevent rejection of renal transplants. Inhibitors of the interleukin (IL)-17 cytokine are indicated for psoriasis, psoriatic arthritis and ankylosing spondylitis and anti- IL-23 drugs for psoriasis. Serious infections occur in 4.2% to 25.0% of co-stimulatory inhibitors and 1.0% to 2.0% with IL-17 or IL-23 inhibitors. Underlying disease, steroid dose greater than 7.5 to 10.0 mg, and comorbidities influence risk in individual patients. Opportunistic infections or reactivation of tuberculosis are rare.
引用
收藏
页码：179 / +
页数：12
相关论文
共 81 条
  • [71] No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis
    Strober, B. E.
    Langley, R. G. B.
    Menter, A.
    Magid, M.
    Porter, B.
    Fox, T.
    Safi, J., Jr.
    Papavassilis, C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : E105 - E107
  • [72] STUCK AE, 1989, REV INFECT DIS, V11, P954
  • [73] Tank ND, 2017, J PHARMACOL PHARMACO, V8, P92, DOI 10.4103/jpp.JPP_155_16
  • [74] Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
    van der Heijde, Desiree
    Wei, James Cheng-Chung
    Dougados, Maxime
    Mease, Philip
    Deodhar, Atul
    Maksymowych, Walter P.
    Van den Bosch, Filip
    Sieper, Joachim
    Tomita, Tetsuya
    Landewe, Robert
    Zhao, Fangyi
    Krishnan, Eswar
    Adams, David H.
    Pangallo, Beth
    Carlier, Hilde
    [J]. LANCET, 2018, 392 (10163) : 2441 - 2451
  • [75] Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis
    Vieira, Maria-Cecilia
    Zwillich, Samuel H.
    Jansen, Jeroen P.
    Smiechowski, Brielan
    Spurden, Dean
    Wallenstein, Gene V.
    [J]. CLINICAL THERAPEUTICS, 2016, 38 (12) : 2628 - 2641
  • [76] Vincenti F, 2016, NEW ENGL J MED, V374, P2600, DOI 10.1056/NEJMc1602859
  • [77] Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia - Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy
    Wolfe, F
    Caplan, L
    Michaud, K
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (02): : 628 - 634
  • [78] Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
    Yang, Eric J.
    Smith, Mary Patricia
    Ly, Karen
    Bhutani, Tina
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1993 - 2000
  • [79] Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare
    Yun, Huifeng
    Xie, Fenglong
    Delzell, Elizabeth
    Levitan, Emily B.
    Chen, Lang
    Lewis, James D.
    Saag, Kenneth G.
    Beukelman, Timothy
    Winthrop, Kevin L.
    Baddley, John W.
    Curtis, Jeffrey R.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68 (01) : 56 - 66
  • [80] Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
    Zachariae, Claus
    Gordon, Kenneth
    Kimball, Alexandra B.
    Lebwohl, Mark
    Blauvelt, Andrew
    Leonardi, Craig
    Braun, Daniel
    McKean-Matthews, Missy
    Burge, Russel
    Cameron, Gregory
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 294 - +
123456789